Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Bevacizumab Stories

2014-01-22 12:26:53

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need RemainsMacular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains SummaryGBI Research has released its research, "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 -...

2014-01-13 08:29:57

CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer. The ongoing open label Phase 2 monotherapy trial is being conducted at Massachusetts General Hospital and the affiliated Harvard teaching hospitals under the direction of principal investigator,...

2014-01-08 08:27:45

Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017 MOUNTAIN VIEW, Calif., Jan. 8, 2014 /PRNewswire/ -- The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...

2013-12-27 23:04:45

In response to an article published by Medical News Today (MNT), Voices Against Brain Cancer discusses a new brain tumor vaccine that is personalized to each patient. New York, NY (PRWEB) December 27, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Medical News Today that discusses a new brain cancer vaccine called HSPPC-96, which is personally molded to each patient’s genetic makeup. According to the...

2013-12-18 23:24:54

RnRMarketResearch.com adds “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth” latest report to its store. Dallas, TX (PRWEB) December 18, 2013 There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin,...

2013-12-16 08:23:17

Analysis of phase 2 trial shows potential increase in survival for glioblastoma patients who received vaccine compared to standard of care; Study results support randomized NCI sponsored trial CHICAGO, Dec. 16, 2013 /PRNewswire-USNewswire/ -- Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care...

2013-12-12 23:00:14

ResearchMoz.us include new market research report "Monoclonal Antibodies Market in Colorectal Cancer to 2019" to its huge collection of research reports. Click here to download detail report at http://www.researchmoz.us/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth-report.html. Albany, New York (PRWEB) December 13, 2013 GBI Research, has released the pharma report -...

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-12-11 08:30:26

Penetration of Avastin in Multiple Market Segments and Approval of Seven Novel Premium-Priced Therapies Will Drive Market Growth, According to Findings from Decision Resources BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin will penetrate nearly all segments of the ovarian cancer market through 2022, driving growth of the...